Evidence map›Paper›PMID 39737976›Full record

ArticleNature communications2024

Spatial transcriptomic analysis drives PET imaging of tight junction protein expression in pancreatic cancer theranostics.

James Wang, Jai Woong Seo, Aris J Kare, Martin Schneider, Mallesh Pandrala, Spencer K Tumbale, Marina N Raie, Gokce Engudar, Nisi Zhang, Yutong Guo and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Next-generation molecular imaging of cardiac fibrosis.The international journal of cardiovascular imaging · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

James Wang *Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.
Jai Woong Seo *Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.ORCID 0000-0002-2732-7498
Aris J Kare *Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.ORCID 0000-0002-4896-2853
Martin SchneiderMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.ORCID 0000-0002-4191-1228
Mallesh PandralaMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.
Spencer K TumbaleMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.ORCID 0000-0002-0616-8280
Marina N RaieMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.ORCID 0000-0002-5549-404X
Gokce EngudarMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.
Nisi ZhangMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.ORCID 0000-0002-7841-5754
Yutong GuoMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.
Xiaoxu ZhongDepartment of Radiation Oncology, Stanford University, 857 Blake Wilbur Drive, Stanford, CA, USA.ORCID 0000-0001-5790-1895
Sofia FerreiraDepartment of Radiation Oncology, Stanford University, 857 Blake Wilbur Drive, Stanford, CA, USA.ORCID 0000-0001-9535-2161
Bo WuMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.
Laura D AttardiDepartment of Radiation Oncology, Stanford University, 857 Blake Wilbur Drive, Stanford, CA, USA.ORCID 0000-0003-1782-9045
Guillem PratxDepartment of Radiation Oncology, Stanford University, 857 Blake Wilbur Drive, Stanford, CA, USA.ORCID 0000-0002-0247-6470
Andrei IagaruNuclear Medicine and Molecular Imaging Division, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.
Ryan L BrunsingDepartment of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.
Gregory W CharvilleDepartment of Pathology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.ORCID 0000-0002-2774-2704
Walter G ParkDepartment of Medicine-Gastroenterology & Hepatology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA.
Katherine W FerraraMolecular Imaging Program at Stanford, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, USA. kwferrar@stanford.edu.ORCID 0000-0002-4976-9107

Funding

Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9M
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapyP01CA244114 · NCI · STANFORD UNIVERSITY · PI KIM, SEUNG K · 2021 to 2025
$10.0M
Stanford Molecular Imaging Scholars (SMIS) ProgramT32CA118681 · NCI · STANFORD UNIVERSITY · PI CRAIG S LEVIN · 2016 to 2026
$4.3M
Imaging Modulation of Immune PhenotypeR01CA250557 · NCI · STANFORD UNIVERSITY · PI FERRARA, KATHERINE W, LEVY, RONALD · 2021 to 2025
$3.2M
HIFU-immunotherapy in pancreatic cancerR01CA253316 · NCI · STANFORD UNIVERSITY · PI FERRARA, KATHERINE W · 2020 to 2024
$3.1M
Development of a theragnostic radiopharmaceutical for pancreatic cancerR01CA289924 · NCI · STANFORD UNIVERSITY · PI Katherine W Ferrara · 2024 to 2026
$1.9M
NCI NIH HHS P01 CA244114NCI NIH HHS R01 CA250557NCI NIH HHS R01 CA253316NCI NIH HHS R01 CA289924NCI NIH HHS T32 CA118681NIGMS NIH HHS T32 GM007276U.S. Department of Health & Human Services | National Institutes of Health (NIH) NIGMS5T32GM007276, NIHR01CA250557, R01CA289924 and R01CA253316
6 · The paper itself

Abstract

Molecular imaging using positron emission tomography (PET) provides sensitive detection and mapping of molecular targets. While cancer-associated fibroblasts and integrins have been proposed as targets for imaging of pancreatic ductal adenocarcinoma (PDAC), herein, spatial transcriptomics and proteomics of human surgical samples are applied to select PDAC targets. We find that selected cancer cell surface markers are spatially correlated and provide specific cancer localization, whereas the spatial correlation between cancer markers and immune-related or fibroblast markers is low. Claudin-4 expression increases ~16 fold in cancer as compared with normal pancreas, and tight junction localization confers low background for imaging in normal tissue. We develop a peptide-based molecular imaging agent targeted to claudin-4 with accumulation to ~25% injected activity per cubic centimeter (IA/cc) in metastases and ~18% IA/cc in tumors. Our work motivates a data-driven approach to selection of molecular targets.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsPositron-Emission TomographyAnimalsBiomarkers, TumorCell Line, TumorClaudin-4FemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiceMolecular ImagingProteomicsTight Junction ProteinsTranscriptomeBiomarkers, TumorClaudin-4CLDN4 protein, humanTight Junction Proteins

Identifiers

PMID39737976
PMCPMC11686138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.